Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases
The outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB) from March 2017 to June 2020 were analyzed in this retrospective study. Anti-thymocyte globulin(ATG) was administere...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.980464/full |
| _version_ | 1817997415456702464 |
|---|---|
| author | Cong Zeng Cong Zeng Cong Zeng Cong Zeng Yan Chen Yan Chen Yan Chen Yan Chen Juan Hua Juan Hua Juan Hua Juan Hua Yi Liu Yi Liu Yi Liu Yi Liu Ting-ting Cheng Ting-ting Cheng Ting-ting Cheng Ting-ting Cheng Xia Ma Xia Ma Xia Ma Xia Ma Xu Chen Xu Chen Xu Chen Xu Chen Shi-yu Wang Shi-yu Wang Shi-yu Wang Shi-yu Wang Ya-jing Xu Ya-jing Xu Ya-jing Xu Ya-jing Xu |
| author_facet | Cong Zeng Cong Zeng Cong Zeng Cong Zeng Yan Chen Yan Chen Yan Chen Yan Chen Juan Hua Juan Hua Juan Hua Juan Hua Yi Liu Yi Liu Yi Liu Yi Liu Ting-ting Cheng Ting-ting Cheng Ting-ting Cheng Ting-ting Cheng Xia Ma Xia Ma Xia Ma Xia Ma Xu Chen Xu Chen Xu Chen Xu Chen Shi-yu Wang Shi-yu Wang Shi-yu Wang Shi-yu Wang Ya-jing Xu Ya-jing Xu Ya-jing Xu Ya-jing Xu |
| author_sort | Cong Zeng |
| collection | DOAJ |
| description | The outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB) from March 2017 to June 2020 were analyzed in this retrospective study. Anti-thymocyte globulin(ATG) was administered at a dose of 7.5 mg/kg. The median time for neutrophil and platelet engraftment was 13(range: 8-22) days and 14(range: 8-103) days, respectively. The 30-day cumulative incidence of neutrophil engraftment was 100%, and the 100-day cumulative incidence of platelet engraftment was 95%. All patients achieved complete haploidentical peripheral blood stem cell engraftment, and no cord blood chimerism was observed. The cumulative incidence of grades II-IV and grades III-IV acute graft-versus-host disease (aGVHD) on 100-day was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%), respectively. The estimated cumulative incidence of chronic GVHD (cGVHD) and moderate-severe cGVHD at 3-year was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively. The estimated 3-year cumulative incidence of relapse and non-relapse mortality was 18.8%(95%CI: 10.0%–29.7%) and 17.8%(95%CI: 9.9%–27.5%), respectively. The estimated 3-year probabilities of overall survival, disease-free survival, GVHD/relapse-free survival were 77.6%(95%CI: 68.3%–88.1%), 63.4%(95%CI: 52.6%–76.5%), and 55.5%(95%CI: 44.8%–68.7%), respectively. These satisfying results suggested that haplo-PBSCT combined with UCB is an alternative transplantation protocol for hematologic malignancies. |
| first_indexed | 2024-04-14T02:37:52Z |
| format | Article |
| id | doaj.art-7b2fd4ed61644a4c9c1c0434ba891c37 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-14T02:37:52Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7b2fd4ed61644a4c9c1c0434ba891c372022-12-22T02:17:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.980464980464Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 casesCong Zeng0Cong Zeng1Cong Zeng2Cong Zeng3Yan Chen4Yan Chen5Yan Chen6Yan Chen7Juan Hua8Juan Hua9Juan Hua10Juan Hua11Yi Liu12Yi Liu13Yi Liu14Yi Liu15Ting-ting Cheng16Ting-ting Cheng17Ting-ting Cheng18Ting-ting Cheng19Xia Ma20Xia Ma21Xia Ma22Xia Ma23Xu Chen24Xu Chen25Xu Chen26Xu Chen27Shi-yu Wang28Shi-yu Wang29Shi-yu Wang30Shi-yu Wang31Ya-jing Xu32Ya-jing Xu33Ya-jing Xu34Ya-jing Xu35Department of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, ChinaHunan Hematologic Neoplasms Clinical Medical Research Center, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Changsha, ChinaThe outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB) from March 2017 to June 2020 were analyzed in this retrospective study. Anti-thymocyte globulin(ATG) was administered at a dose of 7.5 mg/kg. The median time for neutrophil and platelet engraftment was 13(range: 8-22) days and 14(range: 8-103) days, respectively. The 30-day cumulative incidence of neutrophil engraftment was 100%, and the 100-day cumulative incidence of platelet engraftment was 95%. All patients achieved complete haploidentical peripheral blood stem cell engraftment, and no cord blood chimerism was observed. The cumulative incidence of grades II-IV and grades III-IV acute graft-versus-host disease (aGVHD) on 100-day was 26.3%(95%CI: 17.2%–36.3%) and 5.0%(95%CI: 1.6%–11.4%), respectively. The estimated cumulative incidence of chronic GVHD (cGVHD) and moderate-severe cGVHD at 3-year was 43.3%(95%CI: 31.6%–54.4%) and 16.0%(95%CI: 8.7%–25.2%), respectively. The estimated 3-year cumulative incidence of relapse and non-relapse mortality was 18.8%(95%CI: 10.0%–29.7%) and 17.8%(95%CI: 9.9%–27.5%), respectively. The estimated 3-year probabilities of overall survival, disease-free survival, GVHD/relapse-free survival were 77.6%(95%CI: 68.3%–88.1%), 63.4%(95%CI: 52.6%–76.5%), and 55.5%(95%CI: 44.8%–68.7%), respectively. These satisfying results suggested that haplo-PBSCT combined with UCB is an alternative transplantation protocol for hematologic malignancies.https://www.frontiersin.org/articles/10.3389/fimmu.2022.980464/fullperipheral bloodcord bloodhaploidentical donorallogeneic hematopoietic stem cell transplantationhematologic malignancy |
| spellingShingle | Cong Zeng Cong Zeng Cong Zeng Cong Zeng Yan Chen Yan Chen Yan Chen Yan Chen Juan Hua Juan Hua Juan Hua Juan Hua Yi Liu Yi Liu Yi Liu Yi Liu Ting-ting Cheng Ting-ting Cheng Ting-ting Cheng Ting-ting Cheng Xia Ma Xia Ma Xia Ma Xia Ma Xu Chen Xu Chen Xu Chen Xu Chen Shi-yu Wang Shi-yu Wang Shi-yu Wang Shi-yu Wang Ya-jing Xu Ya-jing Xu Ya-jing Xu Ya-jing Xu Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases Frontiers in Immunology peripheral blood cord blood haploidentical donor allogeneic hematopoietic stem cell transplantation hematologic malignancy |
| title | Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases |
| title_full | Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases |
| title_fullStr | Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases |
| title_full_unstemmed | Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases |
| title_short | Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases |
| title_sort | haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients a report of 80 cases |
| topic | peripheral blood cord blood haploidentical donor allogeneic hematopoietic stem cell transplantation hematologic malignancy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.980464/full |
| work_keys_str_mv | AT congzeng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT congzeng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT congzeng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT congzeng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yanchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yanchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yanchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yanchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT juanhua haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT juanhua haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT juanhua haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT juanhua haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yiliu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yiliu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yiliu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yiliu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT tingtingcheng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT tingtingcheng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT tingtingcheng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT tingtingcheng haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xiama haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xiama haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xiama haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xiama haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xuchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xuchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xuchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT xuchen haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT shiyuwang haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT shiyuwang haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT shiyuwang haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT shiyuwang haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yajingxu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yajingxu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yajingxu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases AT yajingxu haploidenticalperipheralbloodstemcelltransplantationcombinedwithunrelatedcordbloodinhematologicmalignancypatientsareportof80cases |